Lakefront Biotherapeutics NV current report, Q3 FY2016

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2016. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report incorporates by reference a press release dated September 26, 2016 (Exhibit 99.1).

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the issuance of a press release and does not contain a financial statement or quantitative performance data.

Material Changes

No material financial changes versus prior periods are detailed in this document. The filing is procedural, intended to update the market on the press release issued on September 26, 2016.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, risk factors, or details on contingencies. Investors must refer to the attached Exhibit 99.1 (the press release) for specific operational updates or strategic announcements.

Investor Verification Checklist

  • Verify the content of the press release dated September 26, 2016, referenced as Exhibit 99.1.
  • Confirm the registrant name is Galapagos NV, noting the discrepancy with the provided metadata company name.
  • Check the incorporated Registration Statements (Forms F-3 and S-8) for broader context on capital raising activities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.